Preventing thromboembolic events, while minimizing bleeding risks, remains challenging
when managing patients with atrial fibrillation (AF). Several factors contribute to current …

Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Background: Extremes of body weight may alter exposure to non-vitamin K antagonist oral
anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Background The influence of morbid obesity on mortality in patients receiving anticoagulant
therapy for VTE has not been consistently evaluated. Methods Data from the RIETE …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

Obesity is a major risk factor for atrial fibrillation. It also influences the natural history of the
disease, leading to more persistent forms and poorer ablation outcomes. This article reviews …

Aim To investigate the association of anthropometric parameters [height, weight, body mass
index (BMI), body surface area (BSA), and lean body mass (LBM)] with outcomes in atrial …

Background It is still unclear whether body mass index (BMI) affects bleeding and
cardiovascular events in patients requiring oral anticoagulants (OAC) for atrial fibrillation …